Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 10/20 | 0.48 |
| ▸ | MMP9 | P14780 | 9/20 | 0.48 |
| ▸ | MMP12 | P39900 | 4/20 | 0.48 |
| ▸ | MMP14 | P50281 | 4/20 | 0.48 |
| ▸ | MMP8 | P22894 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP10 | P09238 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1731666 | 1.00 | MMP2 (0.48) | MMP2MMP9MMP12MMP14MMP8 | |
| SCHEMBL1732454 | 0.96 | ALDH1A1 (0.43) | MMP2MMP9MMP12MMP14MMP8 | |
| SCHEMBL1732457 | 0.96 | ALDH1A1 (0.43) | MMP2MMP9MMP12MMP14MMP8 | |
| SCHEMBL1732123 | 0.92 | MMP2 (0.48) | MMP2MMP9MMP12MMP14ALDH1A1 | |
| SCHEMBL1732127 | 0.92 | MMP2 (0.48) | MMP2MMP9MMP12MMP14ALDH1A1 | |
| SCHEMBL1731665 | 0.88 | NPY5R (0.43) | MMP2MMP9ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1732343 | 0.88 | NPY5R (0.43) | MMP2MMP9ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3222057 | 0.84 | PTPN1 (0.48) | MMP2MMP9MMP12MMP14MMP8 | |
| SCHEMBL3222069 | 0.84 | PTPN1 (0.48) | MMP2MMP9MMP12MMP14MMP8 | |
| SCHEMBL1731260 | 0.84 | PTPN1 (0.42) | MMP2MMP9ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492780-B1 | 5-SUBSTITUTED 1,1-DIOXO-¬1,2,5 THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | NOVARTIS AG (CH) | 2011-11-23 | — | — | EP | claimed |
| US-20080139576-A1 | 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives | NOVARTIS AG (CH) | 2008-06-12 | — | — | US | claimed |
| US-7291635-B2 | 5-substituted 1,1-dioxo-1,2,5,-thiadiazolidin-3-one derivatives | NOVARTIS AG (CH) | 2007-11-06 | — | — | US | claimed |
| US-20050090502-A1 | Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents | NOVARTIS AG (CH) | 2005-04-28 | — | — | US | claimed |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | COPPOLA GARY MARK | 2004-02-05 | — | — | US | claimed |
| EP-1492780-B1 | 5-SUBSTITUTED 1,1-DIOXO-¬1,2,5 THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | NOVARTIS AG (CH) | 2011-11-23 | — | — | EP | disclosed |
| EP-2341049-A1 | 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as PTPASE 1B inhibitors | Novartis AG (CH) | 2011-07-06 | — | — | EP | disclosed |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | COPPOLA GARY MARK | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139576-A1 | 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives | PTPRS, PTPRJ, IRS1 | MMP2 1353/4885MMP9 2531/4885MMP12 862/4885 |
| US-20050090502-A1 | Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents | PTPRS, PTPMT1, PTPN1 | MMP2 1458/4885MMP9 2123/4885MMP12 760/4885 |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | PTPRS, PTPA, PTPMT1 | MMP2 1075/4885MMP9 2382/4885MMP12 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.